Table 1 Patient characteristics (n = 105)
Parameter | Total (n = 105) | Full-dose GC (n = 41) | Dose-reduced GC (n = 27) | GCa (n = 37) | P value |
|---|---|---|---|---|---|
Age, years, median (IQR) | 74 (69–79) | 72 (64–77) | 76 (69–80) | 75 (71–80) | 0.0076a* |
Sex, no. (%) | 0.55b | ||||
Male | 80 (76.2) | 29 (70.7) | 22 (81.5) | 29 (78.4) | |
Female | 25 (23.8) | 12 (29.3) | 5 (18.5) | 8 (21.6) | |
ECOG PS, no. (%) | 0.43b | ||||
0 | 82 (68.6) | 31 (75.6) | 18 (66.7) | 23 (62.2) | |
≥ 1 | 33 (31.4) | 10 (24.4) | 9 (33.3) | 14 (37.8) | |
Primary site, no. (%) | 0.0040b* | ||||
Bladder | 44 (41.9) | 26 (63.4) | 10 (37.0) | 8 (21.6) | |
Upper urinary tract | 46 (43.8) | 13 (31.7) | 12 (44.4) | 21 (56.8) | |
Both | 15 (14.3) | 2 (4.9) | 5 (18.5) | 8 (21.6) | |
Serum creatinine, mg/dL, median (IQR)† | 1.04 (0.75–1.38) | 0.75 (0.67–1.02) | 1.11 (0.91–1.39) | 1.36 (0.99–1.55) | 0.0012a* |
eGFR, mL/min/1.73 m2, median (IQR)† | 49.9 (39.8–67.3) | 68.1 (54.8–84.3) | 45.2 (39.3–61.2) | 39.3 (34.0–48.6) | < 0.0001a* |
Resection of primary site, no. (%) | 52 (49.5) | 19 (46.3) | 10 (37.0) | 23 (62.2) | 0.12b |
Prior neoadjuvant/adjuvant chemotherapy, no. (%) | 11 (10.5) | 4 (9.8) | 2 (7.4) | 5 (13.5) | 0.72b |
Lymph node metastasis, no. (%) | 70 (66.7) | 25 (61.0) | 23 (85.2) | 22 (59.5) | 0.060b |
Visceral metastasis, no. (%) | 56 (53.3) | 23 (56.1) | 12 (44.4) | 21 (56.8) | 0.56b |
Lung metastasis, no. (%) | 37 (35.2) | 18 (43.9) | 8 (29.6) | 11 (29.7) | 0.33b |
Bone metastasis, no. (%) | 14 (13.3) | 5 (12.2) | 2 (7.41) | 7 (18.9) | 0.39b |
Liver metastasis, no. (%) | 13 (12.4) | 2 (4.9) | 3 (11.1) | 8 (21.6) | 0.79b |
Follow–up duration, months, median (IQR) | 14 (7–24) | 14 (5–28.5) | 15 (8–24) | 11 (6–23) | 0.76a |